17:59 , Oct 19, 2018 |  BC Week In Review  |  Company News

J&J stalls development of antiviral from Alios deal

Johnson & Johnson (NYSE:JNJ) has stalled development of lumicitabine (AL-8176), an antiviral candidate that was a key to its $1.75 billion acquisition of Alios BioPharma Inc. in 2014, and revealed a resulting impairment charge of...
21:43 , Oct 16, 2018 |  BC Extra  |  Company News

J&J stalls development of antiviral from Alios deal

Johnson & Johnson (NYSE:JNJ) has stalled development of lumicitabine (AL-8176), an antiviral candidate that was a key to its $1.75 billion acquisition of Alios BioPharma Inc. in 2014, and revealed a resulting impairment charge of...
20:48 , Oct 5, 2018 |  BC Week In Review  |  Company News

Roche gains CD25 program via Tusk takeout

Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to receive €585 million ($686.8 million) in undisclosed milestones. Roche will gain...
21:32 , Sep 28, 2018 |  BC Extra  |  Company News

Roche gains CD25 program via Tusk takeout

Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to receive €585 million ($686.8 million) in undisclosed milestones. Roche will gain...
16:34 , Sep 21, 2018 |  BC Week In Review  |  Company News

Molecular Templates extends deal with Takeda on engineered toxin bodies

Building on a previous discovery collaboration, Molecular Templates Inc. (NASDAQ:MTEM) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered Sept. 19 to develop CD38-targeting engineered toxin bodies (ETBs) to treat multiple myeloma. Molecular Templates will receive $30...
22:39 , Sep 19, 2018 |  BC Extra  |  Company News

Molecular Templates gains on deal with Takeda

Building on a previous discovery collaboration, Molecular Templates Inc. (NASDAQ:MTEM) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered Wednesday to develop CD38-targeting engineered toxin bodies (ETBs) to treat multiple myeloma. Molecular Templates will receive $30 million...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...
23:59 , Jun 21, 2018 |  BC Innovations  |  Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
18:02 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genmab, Janssen discontinue Darzalex combo trials

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors. The studies include the open-label, international Phase Ib/II CALLISTO/LUC2001 trial, which is...